
Estimates are already in the high end of Lundbeck's own prognosis in the prelude to the company's third quarter results, which will be released on Wednesday morning.
Analysts will be paying close attention to four of Lundbeck's key products: the antidepressant Brintellix; the schizophrenia drug Abilify Maintena; Rexulti, which is used in schizophrenia and depression treatments; and Veypti, a migraine preventive therapy.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app